Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Past Presentations
-
Delivery of Antisense Oligonucleotides to Satellite Cells in Preclinical Models of Duchenne Muscular Dystrophy
- By: Sweta Girgenrath, PhD, Vice President, Therapeutic Research and External Innovation Lead, Entrada Therapeutics
- At: MDA Clinical & Scientific Conference
- On: March 11, 2026
DownloadMarch 11, 2026 -
Preclinical Efficacy of ENTR-601-51 for the Treatment of Exon 51 Skip-Amenable Duchenne Muscular Dystrophy
- By: Michael St. Andre, PhD, Principal Scientist, Entrada Therapeutics
- At: MDA Clinical & Scientific Conference
- On: March 10, 2026
DownloadMarch 10, 2026 -
Preclinical Efficacy of ENTR-601-50, a Novel EEV™-Oligonucleotide Construct for the Treatment of Exon 50 Skip–Amenable Duchenne Muscular Dystrophy
- By: Haoming Liu, PhD, Principal Scientist, Entrada Therapeutics
- At: 21st Annual Meeting of the Oligonucleotide Therapeutics Society
- On: October 19, 2025
DownloadOctober 19, 2025 -
ELEVATE-44-201, a Phase 1/2b Study to Assess the Safety and Efficacy of ENTR-601-44 in Patients With DMD Amenable to Exon 44 Skipping
- By: Laurent Servais, MD, PhD, MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research, University of Oxford, and Neuromuscular Reference Centre, University Hospital of Liège
- At: 30th Annual Congress of the World Muscle Society
- On: October 7, 2025
DownloadOctober 7, 2025 -
ELEVATE-45-201, a Phase 1/2b Study to Assess the Safety and Efficacy of ENTR-601-45 in Patients With DMD Amenable to Exon 45 Skipping
- By: Giovanni Barnello, MD, PhD, UCL Great Ormond Street Institute of Child Health
- At: 30th Annual Congress of the World Muscle Society
- On: October 7, 2025
DownloadOctober 7, 2025 -
Preclinical Efficacy of ENTR-601-50, a Novel EEV™-Oligonucleotide Construct for the Treatment of Exon 50 Skip–Amenable Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Therapeutic Research and External Innovation Lead, Entrada Therapeutics
- At: 30th Annual Congress of the World Muscle Society
- On: October 7, 2025
DownloadOctober 7, 2025